|
|
 |
| Whole Blood CD19 MicroBeads |
|
| Description |
Whole Blood CD19 MicroBeads were developed for rapid positive selection of CD19+ cells directly from whole blood or bone marrow. No sample preparation is required, including density gradient centrifugation or erythrocyte lysis. Anticoagulated cell samples of 0.25–15 mL are labeled with Whole Blood CD19 MicroBeads to be subsequently separated with the autoMACS™ Pro Separator or the autoMACS Separator, or using the Whole Blood Column Kit..
The CD19 antigen is expressed from early pro-B cells to the B cell blast stage. It is also present on most malignant B cells. The expression of the CD19 antigen is down-regulated upon terminal differentiation of B cells to plasma cells. |
| Applications |
Whole Blood MicroBeads allow the fast isolation of CD19+ cells directly from whole blood or bone marrow, thus minimizing hands-on time and maximizing yield of target cells. Whole Blood MicroBeads in combination with the autoMACS™ Separators allow standardization of the cell separation procedure and safe handling of hazardous samples. The purified CD19+ cells are well-suited for further flow cytometric, functional, or molecular analysis including lineage-specific chimerism analysis after allogeneic stem cell transplantation1,2,3.
For more information on MACS® Whole Blood MicroBeads click here. |
| |
| Figure 1 |
| CD19+ cells were separated from whole blood using Whole Blood CD19 MicroBeads and the autoMACS™ Separator with program Posseld2. Cells were stained with CD20-FITC and CD45-PE. |
 |
 |
|
|
|
|
| My favorites |
| Your current favorite list is empty. |
| Products |
| Whole Blood CD19 MicroBeads, human |
| For research use only |
for 40 mL whole blood
Download data sheet
130-090-880
|
|
| MACS References |
| 1. Köhl et al. (2003) Leukemia 17: 232–336.[2571] |
| 2. Adams et al. (2004) MACS&more 8/2: 16–17.[7423] |
| 3. Meyer et al. (2006) Blood 109: 374–382.[9414] |
|
|